MedPath

Tiopronin

Generic Name
Tiopronin
Brand Names
Thiola
Drug Type
Small Molecule
Chemical Formula
C5H9NO3S
CAS Number
1953-02-2
Unique Ingredient Identifier
C5W04GO61S
Background

Tiopronin is a prescription thiol drug used primarily in the treatment of severe homozygous cystinuria. Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation. Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation. It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization. As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. Tiopronin is dosed on an individual basis using close monitoring of urinary cystine concentrations and urinary output.

Tiopronin may also be used to bind metal nanoparticles in Wilson's disease, which is an overload of copper in the body. It has been investigated for use in the treatment of arthritis and as a neuroprotective agent in aneurysmal subarachnoid hemorrhage.

Indication

Tiopronin is indicated for the prevention of kidney stone formation in patients with severe homozygous cystinuria consisting of a urinary cystine concentration greater than 500 mg/day, and who have failed treatment with non-pharmacological measures of increased fluid intake, decreased sodium and protein intake, and urine alkalinization.

Associated Conditions
Kidney Stones
Associated Therapies
-

Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria

Phase 2
Completed
Conditions
Cystinuria
Interventions
First Posted Date
2018-09-10
Last Posted Date
2021-12-17
Lead Sponsor
NYU Langone Health
Target Recruit Count
10
Registration Number
NCT03663855
Locations
🇺🇸

New York University School of Medicine, New York, New York, United States

The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage

Phase 2
Completed
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Drug: Placebo
Drug: Tiopronin
First Posted Date
2010-03-30
Last Posted Date
2020-09-03
Lead Sponsor
E. Sander Connolly
Target Recruit Count
60
Registration Number
NCT01095731
Locations
🇺🇸

Columbia University Medical Center, New York, New York, United States

🇺🇸

University of Washington, Seattle, Washington, United States

🇺🇸

University of Florida, Gainesville, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath